Editorial: HIV-1 reverse transcriptase inhibitors: Drug resistance and drug development

Current Pharmaceutical Design

Volumn 12, Issue 15, 2006, Pages 1809-1810

  Sluis Cremer, Nicolar ^a   Ross, Ted ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; DNA POLYMERASE; DOUBLE STRANDED DNA; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 33646495558     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873635     Document Type: Editorial

References (8)

1. Menéndez-Arias L, Matamoros T, Cases-González, CE, Insertions and deletions in HIV-1 reverse transcriptase: Consequences for drug resistance and viral fitness. Curr Pharm Design 2006; 12(15): 1811-1825.
2. Smith AJ, Scott WA, The influence of natural substrates and inhibitors on the nucleotide dependent excision activity of HIV-1 reverse transcriptase in the infected cell. Curr Pharm Design 2006; 12(15): 1827-1841.
3. Kroeger Smith MB, Smith Jr RH, Jorgensen WL, Assault on resistance, the use of computacional chemistry in the development of anti-HIV drugs. Curr Pharm Design 2006; 12(15): 1843-1856.
4. Basavapathruni A, Anderson KS, Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly. Curr Pharm Design 2006; 12(15): 1857-1865.
5. Götte M, Effects of Nucleotides and Nucleotide Analogue Inhibitors of HIV-1 Reverse Transcriptase in a Ratchet Model of Polymerase Translocation. Curr Pharm Design 2006; 12(15): 1867-1877.
6. Srivastava S, Sluis-Cremer N, Tachedjian G, Dimerization of Human Immunodeficiency Virus type 1 Reverse Transcriptase as an Antiviral Target. Curr Pharm Design 2006; 12(15): 1879-1894.
7. Camarasa MJ, Velázquez S, San-Félix A, Pérez-Pérez MJ, Bonache MC and De Castro S, TSAO Derivatives, Inhibitors of HIV-1 Reverse Transcriptase Dimerization: Recent Progress. Curr Pharm Design 2006; 12(15): 1895-1907.
8. Klumpp K, Mirzadegan T, Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Design 2006; 12(15): 1909-1922.